Reviewed 10 November 2026 for medical education. This material is not a prescribing protocol; apply local clinical guidance and individual assessment.
Overview
Osteoporosis pharmacotherapy reduces fracture risk by decreasing bone resorption or stimulating formation. Treatment decisions combine prior fractures, bone mineral density (BMD), clinical risk, kidney function, adverse effects and individual preference [1–3].
Correct classification and molecular actions
- Nitrogen-containing bisphosphonates: alendronate, risedronate, ibandronate, pamidronate and zoledronic acid. They bind hydroxyapatite and inhibit osteoclast farnesyl-pyrophosphate synthase in the mevalonate pathway, impairing protein prenylation and bone resorption.
- Non-nitrogen bisphosphonates: etidronate, clodronate and tiludronate; their metabolites disrupt osteoclast function. The earlier article incorrectly labelled clodronate and etidronate as nitrogen-containing drugs.
- Teriparatide: recombinant human parathyroid hormone fragment PTH(1–34).
- Abaloparatide: synthetic analogue of parathyroid hormone-related peptide (PTHrP), not a PTH(1–34) analogue.
Intermittent PTH1-receptor stimulation favors bone formation; sustained PTH elevation can increase resorption [1].
Selection and comparative effectiveness
Alendronate, risedronate and zoledronate are widely recommended cost-effective antiresorptive options. Ibandronate has evidence for vertebral-fracture reduction but not reliable hip-fracture reduction. Teriparatide, abaloparatide or the sclerostin inhibitor romosozumab may be considered in patients at very high fracture risk, especially with vertebral fractures [2,3]. Denosumab is a separate RANKL inhibitor: it is not a bisphosphonate, and unplanned cessation can cause rebound vertebral fractures [2].
Administration and pharmacokinetics
Oral alendronate and risedronate have very low bioavailability and must be taken with plain water while fasting, with required upright posture and spacing before food/other medicines as specified for the product. IV zoledronate avoids gastrointestinal absorption but warrants kidney assessment and hydration review. Bisphosphonates accumulate on bone and persist for years. Teriparatide and abaloparatide are daily subcutaneous injections; treatment duration and indication depend on jurisdiction [1,2].
Safety and precautions
Oral bisphosphonates can cause esophagitis; avoid when esophageal transit disorders or inability to remain upright make administration unsafe. Hypocalcemia must be corrected before potent antiresorptives. Rare osteonecrosis of the jaw and atypical femoral fracture are associated with prolonged antiresorptive therapy; their rarity should be interpreted against fracture-prevention benefit. PTH analogues may cause transient hypercalcemia, orthostasis and nausea; evaluate contraindications such as skeletal malignancy or prior skeletal radiation using the precise label [1,2].
Monitoring and sequencing
Assess calcium/vitamin D sufficiency, renal function, BMD and fracture history. Reassess bisphosphonate-treated patients after roughly 3–5 years and consider a supervised pause only when fracture risk permits; this is not a denosumab strategy. After completing anabolic therapy, promptly initiate an antiresorptive to preserve BMD and fracture benefit [2,3].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- National Osteoporosis Guideline Group. NOGG 2024: clinical guideline for the prevention and treatment of osteoporosis. Updated September 2024. Available from: https://www.nogg.org.uk/full-guideline/section-6-pharmacological-treatment-options
- Endocrine Society. Pharmacological management of osteoporosis in postmenopausal women: guideline resources. Available from: https://www.endocrine.org/clinical-practice-guidelines/osteoporosis-in-postmenopausal-women
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.